Results 1 - 10 of 21 : 1 2 3 Next
Teva and AstraZeneca's Drama Concludes
But investors are still left in the dark.
Check out these newly minted five-star stocks.
A nod from the FDA and a new partnership boost Indevus shares. Where to, now?
Teva and FDA's Never-Ending Court Battle
Teva looses latest battle against the FDA.
The generic-drug company decides to keep its specialty pharmaceutical subsidiary.
Tapping the Brakes on the Teva-Barr Deal
The FTC wants more information before it offers its approval.
Now That's the Way to Spin Off a Company
Sell off the spin-off for more than the company was worth before the breakup.
As the FDA Generics Office Turns
The FDA reluctantly gives Teva a 180-day exclusive period to sell generic Risperdal.
Teva persuades a court to order the FDA to award it a marketing exclusivity for generic Risperdal.
Teva Wants the FDA to Do What?
Teva wants the FDA to reinstate another drugmaker's patent.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK